HIV/AIDS Drugs Sold Despite Known Dangerous Side Effects
Serious Side Effects Kept Secret
Evidence is mounting that Gilead Science, the sole maker of HIV/AIDS medications using a formulation known as tenofotenofovir disoproxil fumarate (TDF), illegally withheld test results for more than a decade showing the drug was highly dangerous. According to court documents, patients taking the drugs developed the following serious medical complications in unusually high numbers:
- Bone fractures
- Chronic kidney disease (CKD) or declining kidney function
- Acute kidney injury (AKI) or acute renal failure (ARF)
TDF Lawsuits Underway for Injured Patients
Lawsuits filed in several state and federal courts allege that Gilead Science knowingly injured patients by keeping alarming tenofovir disoproxil fumerate (TDF) test results secret, and by failing to warn doctors that a safer alternative existed. The lawsuits further allege Gilead Science developed and then intentionally delayed the market introduction of a safer HIV/AIDS treatment formulation known as tenofovir alafenamide fumarate (TAF), later marketed as the drugs Genvoya and Odefsey. The lawsuits claim that the motive behind the delay was to maximize profits from TDF drug sales (in the neighborhood of $11 billion annually) before patents on these drugs expired.
Urgent Action Required
Putting profits before the wellbeing of patients is immoral as well as illegal. If you have been diagnosed with bone loss or kidney damage after taking Viread, Truvada, Atripla, Complera, or Stribild, contact The Joel Bieber Firm as soon as possible about your rights under the law. Consultations are always free of charge and may lead to your being compensated by Gilead Science for related medical and other expenses. Family members of patients who may have died as a result of these complications also may be eligible for compensation. Don’t delay. Call us now for free legal advice and for more information.
Call Toll Free: 888-777-5635
If you prefer to contact us via email, please take a moment to fill out the short form below.